Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 9/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.44 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.38 |
| ▸ | PDE2A | O00408 | 2/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3900693 | 0.75 | CYP2A6 (0.51) | CYP11B1CYP11B2 | |
| SCHEMBL3904414 | 0.71 | ALDH1A1 (0.32) | — | |
| SCHEMBL30546874 | 0.71 | CYP2A6 (0.46) | CYP11B1CYP11B2MAP4K1PTGS2PDE10A | |
| SCHEMBL29988790 | 0.71 | TDO2 (0.49) | CYP11B1CYP11B2PTGS2ABL1 | |
| SCHEMBL3421743 | 0.71 | TDO2 (0.49) | CYP11B1CYP11B2PTGS2ABL1 | |
| SCHEMBL19937167 | 0.70 | MBNL1 (0.51) | PDE10A | |
| SCHEMBL26104342 | 0.69 | CYP17A1 (0.48) | PDE10A | |
| SCHEMBL16385407 | 0.69 | CYP11B1 (0.54) | CYP11B1CYP11B2ABL1DHODH | |
| SCHEMBL30494306 | 0.69 | CYP11B1 (0.54) | CYP11B1CYP11B2MAP4K1PTGS2ABL1 | |
| SCHEMBL30494380 | 0.69 | CYP11B1 (0.54) | CYP11B1CYP11B2ABL1DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312313-A1 | COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-12-17 | — | — | US | disclosed |
| US-7560558-B2 | Compound having TGFβ inhibitory activity and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-07-14 | — | — | US | disclosed |
| US-20060111375-A1 | Compound having tgfß inhibitory activity and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-05-25 | — | — | US | disclosed |
| EP-1548008-A1 | COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111375-A1 | Compound having tgfß inhibitory activity and medicinal composition containing the same | TGFB1, TGFBR1, TGFBR2 | CYP11B1 590/4885CYP11B2 759/4885MAP4K1 2596/4885 |
| US-20090312313-A1 | COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | TGFB1, TGFBR1, TGFBR2 | CYP11B1 636/4885CYP11B2 799/4885MAP4K1 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.